The global urinary tract infection testing market size was estimated at USD 579.23 million in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 4.4% from 2023 to 2030. The urinary tract infection (UTI) testing market is witnessing growth due to factors such as rising disease burden, rapid technological advancements, increasing geriatric population, and R&D investments by key players to introduce self-testing products. Urinary tract infection is becoming a common global concern. According to research studies, UTI occurs in one in five adult women at some point in their life. In the U.S., about 25%-40% of women aged 20-40 have suffered a UTI. More than 6 million UTI patient visits to physicians every year in the U.S. Out of which around 20% of those visits are to the emergency department.
Women are more prone to UTIs than men.The incidence of disease in adult women tends to increase with age. Infection rate is comparatively high in postmenopausal women, owing to factors such as changes in vaginal flora, which provides a favorable environment for growth of certain pathogens.
Introduction of portable handheld equipment and availability of at-home sample collection kits & self-testing kits for UTI testing are among factors likely to boost adoption. For instance, in May 2020, Healthy.io Ltd. launched home test kit in the UK. Moreover, point-of-care testing for UTI will be a key growth area, which is expected to increase investments by companies. Moreover, researchers are developing technologically advanced products for disease diagnosis, which are expected to be commercialized in the space in the coming years. In January 2020, engineers at the University of Bath developed a test for UTI using a smartphone camera. They have claimed that it can detect E.coli presence in a urine sample in less than 25 minutes.
The space experienced a setback due to the COVID-19 pandemic. Amid the pandemic, hospitals and clinics have reported a decrease in the number of urinary tract infection testing. However, in several countries globally, the effect of COVID-19 declined post the second quarter of 2021, which helped the market regain traction.
However, false results associated with UTI testing may hamper space growth. According to research article published by CUTIC, rapid tests or dipstick tests can give false-positive results in one out of five patients. Such factors can hamper their reliability, slowing down space growth. In addition, an advanced automated system can also provide false results. Nevertheless, the rate of false results is relatively very less in the case of an advanced system.
The cystitis segment dominated the market with a share of 41.42% in 2022. This can be attributed to high incidence & recurrence rate of cystitis, increased number of product approvals, and high number of diabetes patients who are more prone to cystitis. According to NCBI’s epidemiology report, globally, acute cystitis occurs in about 10 out of 100 women every year. In addition, its recurrence rate is also high in women; half of the women affected by cystitis have it again within a year.
In addition, pyelonephritis is anticipated to be the fastest-growing segment in the coming years and is expected to grow at a significant CAGR due to its growing prevalence.According to NCBI statistics, in the U.S., more than 250,000 cases of pyelonephritis are diagnosed every year. The study further suggested that across the globe, in women aged 18 years to 49 years, there are around 28 pyelonephritis cases per 10,000 individuals.
The reference laboratories segment held a share of 26.66% in 2022 attributed to the ongoing efforts of reference laboratories to enhance patient outcomes by offering diagnostic facilities at retail level. Moreover, reference labs can run large volumes of diagnostic tests at a faster rate and offer better outcomes at comparatively lower prices, which is expected to provide economies of scale to service providers. In addition, emerging players providing standalone or reference clinical lab services are expected to contribute to rapid segment growth.
Urogynecologists segment is expected to grow at a fastest CAGR over the forecast period. Due to ongoing efforts to improve patient outcomes by providing diagnostic facilities. It is a recently emerging field that is growing rapidly in developed economies. However, there is a dearth of urogynecologists in underdeveloped and developing economies, which can slow down market growth. Practices in this field are focused on complicated UTIs among females. The number of urogynecologists is anticipated to grow at a high rate over the forecast period, which can be attributed to greater share of female UTIs over male UTIs.
In 2022, North America dominated the overall UTI testing market in terms of value, accounting for a share of nearly 33.94%. This can be attributed tothe high disease burden, availability of infrastructure, increased healthcare expenditure, rapid technological advancements, proactive government initiatives, rise in patient awareness, and presence of major players.
In addition, the Asia Pacific region is expected to witness highest CAGR over the forecast period. The high growth rate can be attributed to rising disease incidence rate, and high geriatric population. Increasing demand for cost-effective diagnostics, and growing population are among factors significantly contributing to market growth. Asia Pacific markets such as Australia and South Korea already have a healthcare reimbursement system that provides coverage for UTI diagnostic tests.
The global UTI testing market is highly competitive, led by companies such as F. Hoffmann-La Roche Ltd. and Sysmex Corporation. Key players are trying to gain market share through product launches and other strategic initiatives. For instance, in May 2023, PathogenDx planned to launch a microarray-based urinary tract infection test. The test will identify 20 associated microbial resistance genes and 26 pathogens in one multiplexed test. For instance, in July 2020, Uqora, Inc. (Pharmavite, LLC), a urinary health biotechnology company, launched a UTI diagnostic and management kit. It includes rapid diagnostic device, Clarify, which is compatible with PoC and homecare settings. Similarly, in May 2020, Healthy.io Ltd. launched urinary tract infection rapid home test kit in the UK. Some of the prominent key players in the global urinary tract infection testing market include:
QIAGEN
Accelerate Diagnostics, Inc.
Bio-Rad Laboratories, Inc.
F. Hoffmann-La Roche Ltd.
Danaher Corporation
Siemens Healthcare GmbH
Randox Laboratories Ltd.
Thermo Fisher Scientific, Inc.
bioMérieux SA
T2 Biosystems, Inc.
Report Attribute |
Details |
Market size value in 2023 |
USD 602.71 million |
Revenue forecast in 2030 |
USD 812.01 million |
Growth rate |
CAGR of 4.4% from 2023 to 2030 |
Base year for estimation |
2022 |
Historical data |
2018 - 2021 |
Forecast period |
2023 - 2030 |
Report updated |
September 2023 |
Quantitative units |
Revenue in USD million and CAGR from 2023 to 2030 |
Report coverage |
Volume & revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Type, end-use, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Country scope |
U.S.; Canada; Germany; U.K.; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; Australia; South Korea; Thailand, Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait |
Key companies profiled |
QIAGEN; Accelerate Diagnostics, Inc.; Bio-Rad Laboratories, Inc.; F. Hoffmann-La Roche Ltd.; Danaher Corporation; Siemens Healthcare GmbH; Randox Laboratories Ltd.; Thermo Fisher Scientific, Inc.; bioMérieux SA; T2 Biosystems, Inc. |
Customization scope |
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the global urinary tract infection testing market report on the basis of type, end-use, and region:
Type Outlook (Revenue, USD Million, 2018 - 2030)
Urethritis
Cystitis
Pyelonephritis
Vaginitis
End-use Outlook (Revenue, USD Million; Volume, Units, 2018 - 2030)
General practitioners (GP's)
Urologists
Urogynecologists
Accountable Care Organization (ACO's)
Hospital Laboratories
Reference Laboratories
Hospital Emergency Departments
Urgent Care
Regional Outlook (Revenue, USD Million, Volume, Units, 2018 - 2030)
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Mexico
Argentina
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
Kuwait
b. The global urinary tract infection testing market size was valued at USD 579.23 million in 2022 and is anticipated to reach USD 602.71 million in 2023.
b. The global urinary tract infection testing market is expected to witness a compound annual growth rate of 4.4% from 2023 to 2030 to reach USD 812.01 million by 2030.
b. Based on type, the cystitis segment accounted for a share of 41.42% in 2022 due to the high incidence & recurrence rate of cystitis and the increasing number of diabetes patients who are more prone to cystitis.
b. Some of the key players in the UTI testing market are QIAGEN; Accelerate Diagnostics, Inc.; Bio-Rad Laboratories, Inc.; F. Hoffmann-La Roche Ltd.; Danaher Corporation; Siemens Healthcare GmbH; Randox Laboratories Ltd.; Thermo Fisher Scientific, Inc.; bioMérieux SA; T2 Biosystems, Inc.
b. The major factors driving UTI testing market growth are the rising disease burden and the launch of at-home and self-testing kits for the early diagnosis of UTI.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
We value your investment and offer free customization with every report to fulfil your exact research needs.